Okay, so we will get started. Thanks for joining us this morning for our quarterly earnings and corporate update. Before we get into the quarterly results, I did want to take a moment to reflect on something that is particularly meaningful to me as the founding CEO. Next week, Avicanna turns 10 years old. 10 years ago, we started with a vision. We started with a dream to advance cannabinoid-based medicine through science and innovation, with a commitment to bringing standardized evidence-based products to patients and ultimately integrating these products and therapies into the standard of care. We set out to be pioneers in an emerging field at a time where medical and regulatory landscape was vague and still evolving. We had the unique opportunity to build that vision in Canada, which was the first G7 country to federally legalize cannabinoid-based medicine and allow such activities to take place.
What started as an idea has evolved into an international biopharmaceutical company with proprietary technologies, 68 commercial SKUs, one pharmaceutical product, several clinical programs, and established commercial operations internationally. More importantly, over the past decade, we have built what we believe is the most comprehensive integrated medical cannabis solution in the industry, bringing together research, development, proprietary products, pharmaceutical innovation, patient support, medical affairs, and of course, all of this is done through MyMedi.ca platform as well. It certainly has not been an easy journey. We have had to adapt, persevere through an emerging industry, challenging regulations, COVID, difficult capital markets, and substantially more challenging than what we imagined when we started. But through it all, we remained consistent and committed to the original vision of standardized cannabinoid-based medicine.
As a founder, I am incredibly proud of what we have endured, but even more proud of what we have accomplished. Today, when I look at what we have built, the patients we have reached, the scientific commercial milestones we achieved, I feel enormous sense of pride and also gratitude. While I recognize that the capital markets and the market valuation does not reflect the progress we have made as a company, I can confidently say that I believe Avicanna is in the strongest position it has ever been. That is a testament to the resilience, dedication, conviction of our team, our partners, and our shareholders, many of which have been with us from the beginning, some of you that are attending the call this morning. I thank you all.
What makes this milestone even more meaningful is that we are entering our second decade with a more mature business, improving financial performance, stronger foundation, and very exciting opportunities ahead of us. Our first decade was about pioneering, persevering, and building. I believe the next decade will be about scaling, executing, and realizing the potential of what we have created. Our third quarter results are a reflection of that progress, and I am pleased to be sharing those with you this morning with Nick. Just a forward-looking statement, disclaimer, but yeah, let us get into it, Nick. Very high-level sort of highlights in terms of the quarter, what we have accomplished, where we are going forward, and we will get into the specifics of these, and then we will leave a few minutes at the end also for Q&A.
We did turn adjusted EBITDA positive in the quarter. Nick will expand on the details of that, and we did so with relatively flat revenue. This is mainly attributed to P&L improvements, cost management, and discipline. We did launch the QUIX portfolio, so I will expand on what the QUIX portfolio means, both commercially and scientifically. We launched the first initial 10 SKUs towards the end of the third quarter. While it did not have significant impact on the revenue because of the sort of the era, we did have pretty important milestones and things to celebrate and discuss.
In terms of MyMedi.ca, we made significant operational efficiencies, but something that I am very proud of is the improvement of Avicanna's proprietary product sales on the platform, which has now increased to 31%, which is a massive difference in comparison to when we took over Medical Cannabis by Shoppers, which was at about 6%. We are making significant advancements on our R&D, but also on the clinical programs that I will also discuss briefly. But as we get into the financials, Nick, do you want to take over the next few slides?
Thank you, Aras, and good morning, everyone. As mentioned, I will briefly walk through our financial results for the third quarter of 2026 before turning it back to Aras for corporate update and closing remarks. Please note that all figures are in Canadian dollars. Revenue for the third quarter was CAD 5.7 million, down 10% from the third quarter of 2025, but up 2% sequentially from the second quarter. The year-over-year decline was driven primarily by the Veterans Affairs Canada reimbursement changes that took effect on April 1st, which reduced the reimbursement amount for veteran patients by 29%, along with lower licensing revenue. The sequential increase is an encouraging sign that MyMedi.ca revenue has stabilized following the VAC changes. Management believes the company has navigated the VAC changes exceptionally well, especially in comparison to other Canadian medical platforms, where revenue decline ranged from 18%-25% based on publicly disclosed information.
The decline at MyMedi.ca was partially offset by 4% year-over-year growth through our proprietary products and portfolio expansion across the retail and medical B2B channels. International revenue also grew 21% year-over-year, led by flower and API sales out of our majority-owned subsidiary, SMGH, which together achieved their highest API and flower quarterly revenue to date. Gross profit was CAD 2.9 million, down CAD 232,000 or 7% year-over-year due to lower revenue from MyMedi.ca and lower high-margin licensing revenue. Despite this, gross margin improved from 49%- 51% year-over-year. This was driven largely by the success of Avicanna's proprietary products on MyMedi.ca, which grew from 19% of platform sales in Q3 2025 to 31% by the end of this quarter. On a year-to-date basis, gross margins were 55%, up from 52% in the same period last year. Sequentially, gross margins declined 57% in Q2 to 51% in Q3.
This reflects a shift from revenue mix from licensing towards product sales, along with higher inventory impairment during the quarter. As a reminder, licensing revenue can be lumpy from quarter to quarter, as it is tied to the timing of larger contract deliverables. G&A expenses declined by CAD 1 million, or 27% year-over-year, and by CAD 777,000 from the second quarter. Roughly two-thirds of the year-over-year decrease resulted from cost reductions, including lower professional fees, reduced human resources in Canada as a result of automations, lower clinical education linked to MyMedi.ca revenue, and lower insurance and IT costs. The remaining savings are attributed to a refundable Scientific Research and Experimental Development, or SR&ED, tax credit of CAD 348,000.
While some of these savings are seasonal or timing-related, we expect the majority to be recurring, and barring changes in legislation, we expect to file a SR&ED claim every year going forward. Adjusted EBITDA was +CAD 222,000 for the quarter, an improvement of CAD 1 million year-over-year, and CAD 577,000 from the second quarter of 2026. This was driven by stronger margins and lower G&A expenses, including the SR&ED credit. Management notes that adjusted EBITDA is a non-IFRS measure. Operating loss improved by CAD 1.1 million, or 80% year-over-year, and CAD 790,000, or 74%, from the second quarter. In addition to better margins and lower G&A, this reflects lower share-based compensation in the quarter. In total, operating expenses were down 30% year-over-year, and net loss before tax narrowed to CAD 301,000, or from CAD 1.4 million in Q3 2025.
I will turn to the next slide, where we will look a little bit deeper at the balance sheet and high-level cash flow. Accounts receivable is relatively flat quarter-over-quarter. Inventory decreased by CAD 650,000, or 15%, as we right-sized inventory levels at MyMedi.ca following the VAC reimbursement changes. Accounts payable and accrued liabilities decreased significantly by CAD 1.4 million, or 16%, as we used available capital to bring payables down to a more manageable operating level. This remains a priority for management heading into Q4. As a result, net working capital improved to a surplus of CAD 114,000 from a deficit of CAD 276,000 at the end of Q2, and from a deficit of CAD 1.3 million at the end of 2025. The improvement reflects stronger operating results and the proceeds from our August private placement, which together allowed us to reduce payables.
Operating cash flow was -CAD 691,000, an improvement of CAD 474,000 from Q2, driven by improved operating results and the inventory reduction, partially offset by the significant pay-down of payables. Financing activities provided CAD 595,000 in the quarter, primarily from our August private placement, while investing activities were minimal. Lastly, subsequent to quarter end, on October 29th, we closed a non-brokered private placement of debenture units for gross proceeds of CAD 2 million. The debentures carry a 13% annual interest rate and mature in one year. Each unit includes warrants exercisable at CAD 0.20 per share. The improved financial performance, better working capital position, and this additional injection of capital have all contributed to a substantially improved financial position for the company, which we believe will enable our business plan and growth initiatives.
Full details are in the subsequent events notes to our financial statements. We intend to use the proceeds for working capital and general corporate purposes. With that, I will turn it back to Aras.
Thank you, Nick. Nick and his team have done a great job in terms of the financial discipline, as you guys can see. As Nick alluded, we wrapped up Q3 in what is relatively the strongest position we've been from a balance sheet perspective. Of course, the additional capital is what's going to enable the rest of the discussion and the progress that we have planned. I just want to take a quick minute to explain the QUIX rapid onset nanotechnology. This is a platform that we built in-house as part of our own scientific platform, and it's also a proprietary formulation that has been filed for patents. It's part of an existing patent portfolio that we have as well. The basic principle here is that cannabinoids are hydrophobic. Cannabinoids have low absorption.
They don't dissolve well in liquids, and therefore, the bioavailability and the onset is often delayed, meaning formulations and products that are basic cannabinoid formulations, which is what's 90% of the Canadian market, is just MCT oil. The concept of the QUIX nanotechnology is to deliver nano cannabinoids within a nano-emulsion, which provides stability, but it provides rapid onset and enhanced absorption. The technology was originally delivered through the nano drops formulation that's in the market. We've since then modified, expanded the portfolio into gummies, capsules, beverages, and a number of other pipeline formulations. This is, in my opinion, one of the, if not one of the most advanced drug delivery technologies for cannabinoids in the market today, and we're very excited about its rollout and its potential moving forward. Thanks, Nick. The initial formulations that we've launched, as I discussed, are the nano drops.
These are beverage infusers. These are basically a very simple way to dose and titrate cannabinoids into water, tea, coffee, and allows patients and consumers to be able to use these products in a much more standardized way. Given the fast onset, the immediate absorption, it's avoiding first-pass metabolism and some of the metabolites that typically cause adverse events when it comes to THC. As I mentioned, through our R&D department, we were able to translate this technology into Rapid Act Capsules. These are soft gel capsules that are now commercial across the Canadian market as well, with, I think, five different SKUs. In addition to that, we converted into food category within the Canadian regulations, and we were able to modify it and deliver fast onset gummies.
Again, one of the major reasons why patients and consumers are inhaling or using combustible type of products that has its own harm and risk is because they want fast onset, and any type of oral edible product typically means an hour and a half to two hours in terms of onset. This technology is designed to deliver and have onset much faster within a 15-20-minute window. Again, very excited about the potential of this technology, not just for the Canadian market, but also internationally.
This is part of Avicanna's harm reduction or treatment optimization plans in which we are trying to, we are not trying, we are delivering options to physicians and to patients, and to consumers in the sense of alternatives for combustible products, which is something that I think will allow us to then expand the market opportunity beyond sort of the traditional kind of cannabinoid-based patient or even consumers. So far we have had some early wins with QUIX, and as I mentioned, we launched QUIX towards the end of Q3. We were able to launch the initial gummy SKUs.
The strategic approach here has been to launch with THC products first, because while there is enhanced bioavailability, stability, things that matters to us as an R&D company, to the patient, to the consumer, what they really have is the sensory experience in terms of the taste, but also they have the experience of onset. By taking a THC-first approach, onset is something that a consumer and a patient can feel. So we started with the gummies. We then were able to launch the initial SKUs of the capsules. Since then, since going into Q4, we have been able to launch a significant number of other SKUs, including a day and night version of the capsules, a couple of other sort of multipacks of the gummies as well. Then as we go into 2027 and later 2026, there are other SKUs that are launching.
The portfolio in total is about 33 SKUs so far. We believe there is going to be a number of other ones we will be adding. Of course, through the MyMedi.ca Platform, we can test these products and see what performs the best, and from there enhance, add additional flavors in the cases of the gummies, and add additional delivery systems across different markets. What is exciting here is that given the potential of these formulations and products as a replacement or as an alternative option to combustible products due to their fast onset technology, we have actually been able to expand across retail channels. We have had significant amount of interest from even Ontario, Alberta, and B.C. for the first time. Pretty excited to have launched those products.
They are doing quite well in the earlier stages. But also, we are expanding these formulations and products across other medical channels. Again, we are seeing competing medical channels pick up these SKUs, which I think is a good signal towards the uniqueness and sort of the entry barriers of the technology that we have. In terms of MyMedi.ca, while we have had to deal with the change in reimbursement, as Nick alluded to, that was a significant reduction of reimbursement from veterans, evidently we can see that the performance of our team and the tactics that we utilize to navigate this has given us the best relative results versus our peers. But with that, we did have a significant revenue decline coming out of MyMedi.ca.
What we've done since then is we've lowered costs, we've increased automation and AI in terms of to be able to raise efficiencies, deal with patient documentation in a much more efficient way, lower human resource costs where possible, lower clinical education fees where possible, and we've been able to do this in a quite rapid rate and to be able to achieve stability within the MyMedi.ca platform. With that, we're seeing incredibly high patient satisfaction rates. We've conducted a 1,500-patient survey where the satisfaction rates were 90% above. This is, I think, leading to things such as record retention rates that we're seeing. Now as we expand MyMedi.ca, and we have initiatives to expand MyMedi.ca, which I will expand on, higher patient retention rates, satisfaction rates are obviously important.
When you combine that with the performance of Avicanna's own proprietary portfolio within MyMedi.ca, we see the combination of our comprehensive sort of medical platform and portfolio performing quite well. This is something that I really wanted to see, and it took us 10 years to get here, and it's something that now we're quite confident and ready to take into other international markets as well. This is just a chart up to Q3. I can tell you that we expect this trend to continue. I can also tell you that when we initially took over, we were in the 6%-10% range at Shoppers Drug Mart, right before we took over. Since then, we've been able to improve the portfolio on MyMedi.ca and, of course, the performance of Avicanna's portfolio on MyMedi.ca.
Why that's important for the audience is that we have a wholesale margin that's attributed to our products that are delivered to MyMedi.ca, and then there's a retail margin. The higher the proportion of Avicanna's products that are being sold on MyMedi.ca the better. We're not doing this by eliminating competing SKUs or by removing other brands. MyMedi.ca still has 230 SKUs, carries about 50 to 60 brands. We're doing this simply by putting up better products that are competing through performance. We're also doing this through patient support. Our patient support team are providing treatment plans, clinical guidelines for our patients. Our medical affairs, where we're educating physicians, we're providing them with clinical guidelines. These are all helping, as well as obviously our education efforts within the platform.
But again, I think there's a lot of credit to be given here to the operations and marketing team as well in terms of the type of products that we continue to test within the MyMedi.ca platform that are giving us these incredible signals. In terms of the MyMedi.ca growth initiatives, the most important one for me, something that I'm personally involved with, is the institutional partnerships, or what we refer to the integrated healthcare program. This is really going beyond the existing medical cannabis physicians or medical cannabis-trained physicians, the medical cannabis clinics, who we obviously continue to have the relationships with. But this is going into active healthcare institutions that are beyond that sort of market opportunity. This is training and educating pain institutions, sleep institutions, hospitals, on how to integrate medical cannabis into their standard of care. Over the last year, we've optimized that process.
We are now embedding the medical documentation process into existing EMRs, so into the existing sort of platforms of these medical institutions. We are taking most of the burden away from physicians that are very limited in time. This is where our pharmacist-led patient support program is quite important, because our pharmacists are the ones that are doing the treatment planning. Therefore, the physicians in the medical community have the comfort that their patients are being steered the right way. We then have a feedback loop with these physicians and medical institutions where we are keeping them updated in terms of the treatment plans of their patients. So far, we have been able to activate this in pilot programs across three different partners. We will be speaking about those more so during the quarter, and there will be more of that to share as we go.
This is a very interesting proof of concept, because today, about 1% of the Canadian population is using medical cannabis or accessing medical cannabis through medical documentation and HCP, healthcare provider involvement. We believe that number has significant room for growth, and we believe that it is better for patients to have pharmacist-led support and the support of their healthcare providers in their medical cannabis treatment. This leads to better outcomes, this can lead to less adverse events, and this is something that we are trying to incorporate into other healthcare institutions through, again, the institutional partnerships. I will quickly touch on some of the scientific and medical affairs efforts. This is led by Karolina and our team. She has done an amazing job in advancing the clinical research programs, and I will touch on the specific studies.
We are making advancements with the phase II pilot study with UHN, which is a really exciting study led by Dr. Hance Clarke, mainly out of Toronto General Hospital. We are in the process for the phase I dose-finding escalation study at University of Calgary. We are involved in a number of other preclinical projects that are being conducted, as well as a real-world evidence study that recently obtained a publication in the Canadian Journal of Pain through UHN as well. Most of these studies, as our long-term shareholders know, are being funded by Canadian grants, but the company is still supporting these projects in parallel with the commercial and business operations that we have. This has led to a much more advanced pharmaceutical pipeline that I will allude to.
One more note, Nick talked about the SR&ED, but I do want to also give credit to our R&D team for the continual development. We are putting out innovative products in Canadian market and expanding beyond that shortly, but we are in a position to continue to put out superior formulations and advanced formulations within the Canadian market through our own internal platform that has been built throughout the years. You are seeing the fruit of that. You are seeing the translation from the lab to the market with what is now 68 SKUs. I do believe we have one of the most advanced scientific platforms related to this industry. In terms of our pharmaceutical pipeline, as you can see, we continue to make progress. This is all being done with internal resources and government grants, so non-dilutive financing.
Many of these studies are being led by principal investigators, so these are some of the key opinion leaders within the Canadian market. Another one of the benefits of being in a federally legal jurisdiction of Canada, we are able to conduct such studies. The programs, I will not get into the details, but the programs are quite advanced. What is unique about these formulations and products is that we have tested these products within MyMedi.ca, within the medical cannabis. These proprietary formulations or drug delivery systems are not only going, have gone through preclinical or going through real-world evidence studies, but are being commercially tested before we advance them into later stages of clinical development. What is really exciting for me is the randomized control trials that we are enrolled in today. Our SEDDS capsules, they are similar to the QUIX technology, a little bit different.
Those particular formulations are now enrolled in the phase I study at University of Calgary and a phase II osteoarthritic pain study that I was alluding to earlier. We expect to have some early results of those next year, and we expect to see these formulations go into further development, the clinical development next year as well. All done in a very efficient and rapid way, again, leveraging off of the Canadian infrastructure and relationships. As we look forward, as I said earlier on, very excited about the results. We are also very excited to have achieved that sort of in this milestone of 10 years. As you guys know, it has been a tough 10 years for the industry, specifically for us as a small company, and we have seen the impact of that in capital markets.
Again, as I said earlier, I believe we are in the strongest position. We have ever been. I believe with the more improved balance sheet and working capital, we can now execute on the business plan that we have, execute on the opportunities that we have tested. We have optimized in Canada and basically take those into both Canadian scale-up, but also international expansion. We are assessing mergers and acquisition opportunities, but we are assessing it from more of a tuck-in strategy into Avicanna. We believe that our scientific platform, our management, our infrastructure, our low-cost supply chain, coming out of Colombia, the combination of which gives Avicanna a unique position to be able to now add other assets and partners, specifically in the world where we can add revenue and market opportunity. We are looking at those.
In terms of the pharmaceutical platform that we just discussed, I believe there is substantial value in that IP, in the formulations, in the drugs that are, one, approved, like Trunerox, and other drugs that are in various stages of development, Health Canada. We believe those drugs ultimately can be co-development opportunities, licensing opportunities, and even FDA pathway. Long way to go, but I believe we are going to see significant milestones related to the pharmaceutical side going into 2027 as well. When I look at the Canadian market, I see the early signals of QUIX and the QUIX portfolio as very promising. I believe we are solving a major issue with the type of formulations we have delivered, which is, again, the delayed onset of the formulations that are on the market. I believe that combustible products and smoking alternatives are going to be something of the future.
We've seen that within the tobacco world, and we're going to see that, I believe, within the cannabis market as well. The early signals are great. The fact that we've had a number of commercial listings already, and that's with the initial stages of the portfolio rollout, is great. How fast we're rolling this out is also another good signal. We have made significant efforts in terms of our margins, but we are going to be making further consolidations related to our manufacturing in Canada. Previously, we've discussed we have 10 manufacturing partners in Canada. We're going to consolidate those efforts to improve margins in the process as well. I'm very excited about the MyMedi.ca integration into standard of care.
I think it's taken us years, but we figured the right pathway to integrate into the standard of care into other medical institutions in a way that's feasible for the physicians, but in a way that we can support further patient population beyond the existing medical market. Internationally, I think we're finally ready. We've spent the last two and a half years at SMGH to prepare for a flower opportunity. Given our cost advantages that we have, we believe we'll have early signals of that this year. Next year, our focus is on scaling that up and sort of further advancing the opportunities that arise from SMGH, not just on flower, but also on API. We are also seeing significant interest for the QUIX and the rest of Avicanna's intellectual property internationally.
The same trends that we're starting to see in Canada and that we expect in Canada are going to take place, I believe, in international markets where clinically differentiated and single-dose formulations and products that avoid or are alternative option for combustible products, we believe are going to be unique. Of course, that's exciting for us, given that we have the intellectual property to protect that, and therefore, entry barriers. Something that's very important for us, and it's a very positive signal, is the recent support we've been able to get from the Canadian government on that front. We've been working with Global Affairs and Trade Commissioner's Office in Canada that are now supporting specifically Avicanna and some of our peers within the industry in opening doors and helping sort of the company expand.
I think that's truly important given the significance or the credibility that comes with Canadian Trade Commissioner's Office supporting in a stigmatized industry. It's also a validation of the maturity of the company and also, of course, our industry here in Canada. Finally, internationally, and this is something that's in parallel with the QUIX and other discussions, is the licensing and pharmaceutical opportunities. We are seeing more and more countries and more and more companies in more and more countries have interest in Avicanna's technology, whether it's the MyMedi.ca platform, the patient support, or our finished products such as the QUIX portfolio, our drug like Trunerox, or even our pharmaceutical pipeline. We're starting to see more and more interest, and I think that's in line with the expectations we have from the United States. We still believe the U.S. rescheduling is going to take place.
I think the U.S. government's been busy for the last while, but I still believe it's going to take place towards the end of this year or early next year. Everything that was presented today has tremendous opportunity in the United States. I'll pause there. I know we typically go fast, but the point of this is also to leave about 15 minutes or so for Q&A before the market opens. I'll give it another minute or so. I have a question from Marc. "I'm aware of how hard you've all been working and appreciate it. It's really encouraging to see the gross margin SG&A progress." Thank you, Marc.
Can you explain why you were comfortable taking on debt at this time?" Marc, I think there's a disconnect in terms of the company's valuation and the reality of the company in terms of its fundamentals. I think the assets, where we're trade, our activities, where we're operating, does not really tie up with the current stock price trading all-time low. While we do want to progress the company advance and execute on our business plan, we did not want to be further dilutive in this range. With that, we felt much more comfortable taking a debt, and we were much more comfortable with our projections and the trajectory we have to be able to service that debt rather than be dilutive.
As you can see, there was a small warrant coverage, but that warrant coverage is at CAD 0.20, which is more than 100% above our stock price. We felt like that was the right step to take at the time. Okay, I'm just trying to read. Our ticker symbol, someone was asking, is AVCN, TSX. That's also on the slide in front of you. The status of the shares of Avicanna, this is all available in our MD&A and our financial statements, but also on Yahoo Finance or any of the basically websites that are covering the stock, typical stocks. We are on the TSX Senior Exchange, so the information related to the stock and the symbol are quite easy to find. More information is also available on our Avicanna website. Another question, "You've had to issue stock in recent years to fund your activities.
First, I'd like to commend you on the prudent approach to the necessary evil. I can't help but wonder we might be at near or the end of this cycle." I tend to agree, and I think we have avoided debt for the last several years. We've had an extremely supportive group of shareholders that have supported the company, and I can tell you it's not fun to conduct CAD 500,000 or CAD 1 million private placements, but we've been prudent to ensure that dilution is limited to what we need to just to essentially get to the next milestone. Today, where we stand, again, the reason why we took the debt was because we believe that we're in a better place to service debt rather than be dilutive.
I believe we are in a position to now put our head down and execute over the next year or so and allow the company to grow, allow the company to execute, allow the fundamentals to further improve, and put out signals that I think is going to create further confidence. Doing that in parallel with not issuing shares in the market or doing private placements or public placements, I think is going to have a positive impact, and that is the purpose of that. I think your read is correct. We believe this is the trajectory that we are on today. "Can you speak about the international opportunities, how Avicanna can bring what it is learning in Canada globally?" I think that is a great question, and I think what we built was really a scientific platform initially that turned into advanced formulations and drug delivery systems and products.
Those products were then delivered to patients originally through Shoppers Drug Mart, and later when we took over Shoppers Drug Mart, it was turned into patient support and medical affairs. I believe medical cannabis is a solution, it is not a product, and I have said this on several occasions. Medical cannabis is something that needs to be delivered with patient support, with patient education, with treatment planning. It is something that needs to be delivered with medical affairs, which is also educating the physicians about the harms, the benefits, clinical guidelines. What we have done in Canada is really build that package. I believe we built that package in the most comprehensive way I have seen in the industry, and now we are in a position to expand that. How we would expand internationally is going to be likely through strategic partnerships.
We do not have the size or scale to go and set up MyMedi.ca and Avicanna and the portfolio everywhere in every market. We believe the right pathway is through strategic partnerships, and those are the type of discussions we are having in emerging markets, the key ones being England, Australia, Brazil, but also potential markets such as the United States. "What are the growth opportunities within Canada? How have you navigated the Veterans Affairs coverage on MyMedi.ca? Do you anticipate any other changes that may impact revenue?" The growth opportunities within Canada are going to be in a very simple fashion through three channels within the short term. MyMedi.ca, and we believe MyMedi.ca growth is something that we have always focused on, but now through the integrated partnerships or institutional partnership model, we expect that to grow beyond the existing cannabis or medical cannabis opportunity.
We believe through our products, so our products are not just sold on MyMedi.ca, but they are expanding across retail and MyMedi.ca platform, but also other medical B2B. Then third, we believe the opportunity in Canada is going to be through licensing and formulations. We are providing access to some of our formulations to some of our strategic partners where they can benefit from perhaps an adult use where they have a larger commercial platform than we do. I still believe Canada is a growth engine. So far, it has been a proof of concept phase for the company, but we are now in a place where we can also expand in Canada. In terms of the Veterans Affairs question, it was quite difficult to navigate an immediate, very, very short notice change, something that should have resulted in about 30% of the sales.
What our strength has been across a number of different tactics that we were able to deliver on, one was the portfolio. We were able to change the portfolio in very short notice to be able to maintain margins and to share some of the revenue reduction or margin reduction with our suppliers. MyMedi.ca is a platform that carries products from many other licensed producers, we were able to share that burden on one end. On the other end, we've been able to reduce operating costs, human resource costs, but also incorporating automation and AI has really helped us. On the other end, it's been dealing with a patient population that's beyond veterans. I think most of the medical platforms in the Canadian market are 90%-99% veteran-centric. We have a huge insurance patient population that aren't veterans.
We have a huge sort of elderly patient population and other patient populations that are coming from our medical partners that are not veterans. We weren't as impacted as well from that side. Do I anticipate further changes? We were expecting Veterans Affairs to make further administrative changes to the process, but they have canceled that for now. We don't see near-term sort of risks. That's why what we're referring to is more of the stability of MyMedi.ca and now time for focus on regrowth. Can you share expectations for the fourth quarter? Can you extrapolate the gross margin percentage in Q4? There's a lot of questions here, so I'm going to answer one at a time. Our expectations for Q4 is to continue to progress with the cost discipline that Nick was alluding to.
We do expect, as you saw, further SKU launches across the Canadian market on QUIX. We expect the trend of the MyMedi.ca percentage of sales on Avicanna's percentage of sales on MyMedi.ca to improve. We also expect to have some early signals of international revenue growth as well through some of our international projects. They always tend to take longer because of the regulatory process, import, export, quotas, specifically coming out of Colombia, but we've been working very hard on that process. Can you explain the source of lower expenses in recent quarters? Nick, you want to tackle that?
Yeah, no, definitely. I think the company's done a great job of looking through contracts that we've had with a number of vendors for a significant period of time and revisiting and renegotiating. I'd say the big rock items are insurance. We reduced that significantly. Our ERP provider was a significant reduction. Then just taking a fulsome look at where we can save across the board, not just in those big rock items, but really digging into the details and in every potential saving line item we can. Also, I'd say the automation that Aras touched on earlier has really saved human resources. We've had a little bit of turnovers, particularly in Canada, but we've been able to fill those positions that previously would have been taken up by efficiencies earned through automations within the team here.
From an expense G&A side, really positive signs that we see as we're going into Q4 and going into next year.
Thanks, Nick. Mark asks, "What are your thoughts about further potential gains from MyMedi.ca mix versus Q3 2026, 2027?" I expect that trend to continue, Mark. This is not because we're like some of the other platforms. We do carry other brands, and we're seeing the performance of other brands also, particularly Oxley, Organigram, others do quite well on MyMedi.ca as well. We're also seeing us competing with some of these more adult-use-focused brands from a medical side and, in many ways, winning market share. I think that trend's going to continue with the expansion of the QUIX portfolio, specifically with the healthcare integrated partnership as we go into these medical institutions and our team are the ones that are doing the treatment planning and we're educating the physicians.
We're naturally going to provide the evidence and training that's related to our products because of the standard and quality that they come with as well. We think that trend is going to continue. I think with the pipeline, there's more QUIX SKUs, but there's also the PwdRx technology that we've now optimized. This is also a fast onset nano-emulsion technology in powder form that is going to be filled into capsules, tablets, sublingual tablets, oral tablets, but also Zyn-style pouches. As that type of pipeline of products continues to expand, we expect that trend to continue. We love the concept of having options for patients, so you're never going to have a MyMedi.ca where the only brands available are Avicanna's, but we do expect to see that trend go towards the 40% to even 50% of the sales. That's something that, again, will expand.
As that goes international, it's going to be much more difficult in an international market if we launch the MyMedi.ca platform to have 60 brands. That level of diversity, number of brands just doesn't exist in international markets. In other markets, I expect the percentage of the Avicanna SKUs on the MyMedi.ca platform internationally to be substantially better as we go as well. Mark also asks, "Is there further gross margin opportunities for MyMedi.ca mix and other parts of the business?" Absolutely. Look, we're still in a small scale, right? If we're in the 50% above gross margins, I think that's a very good sign, probably industry-leading in terms of where we stand. That's, I think, credit to both the diligence in terms of cost management, but it's also credit to the proprietary nature of our products and their high entry barrier.
So, of course, as we scale, as these numbers grow, there is economies of scale. There is consolidation in terms of selecting contract manufacturers that are better at particular things. There is some that are very good at gummies, there is some that are very good at capsules. And as we pivot towards those strategic manufacturing relationships, I think we are going to see further improved margins. As your sales mix continues to increase on MyMedi.ca, you are going to see further consolidated margin improvements. And so, we are seeing that across the board. I think in terms of SG&A, there is always going to be room for improvement.
I think, again, Nick and the team have done a great job in reductions as it is, but I think we have a good foundation now, and really the focus for me specifically is going to be on growth and margin efficiencies rather than just SG&A reduction. And that is something that I think you will start seeing signals of going into Q4. "Can you explain SR&ED, the opportunity terms, magnitude?" Yeah, good question. So, SR&ED, we used to receive SR&ED as well, but SR&ED is basically a government incentive for research and development. And of course, we still do significant amount of research and development, and the Canadian government reimburses 30% of the research and development expenditure of a company. However, they removed. From the beginning, SR&ED was only for private companies. So, when Avicanna did its IPO, we were excluded from that option.
In 2026, the government extended and allowed SR&ED to be available for public companies as well. So, we were able to basically obtain about CAD 330,000 of credit. This not only is something that is going to be replicated next year, but this further incentivizes Avicanna to conduct research and development, which I think is not only leading to immediate term products like QUIX, but it is also leading to long-term value for shareholders in terms of intellectual property and pharmaceutical pipeline. So, that plus the Global Affairs and Trade Commissioner's Office support are two massive incentives that this year have sort of emerged from the Canadian government. I imagine a lot of the tariffs and trade war discussions have incentivized them to care more about the opportunity within the cannabinoid space, but more specifically for us as an R&D-focused company, significant opportunities for cost recovery, but also growth.
Marcus is asking about volume trading yesterday. I think that has to do with tax loss selling, Marcus, is my best bet. We typically see this at the end of the year. At the end of the year, given the share performance, given that we have had two significant large shareholders of the company publicly exit into the market over the last few months and putting the stock at its all-time lows, I am sure somebody saw that as an opportunity for tax loss selling given the performance of other stocks, particularly in the tech sector. That is my best bet. Any other questions? Try to answer those as fast as possible. Okay, folks, think we will take it from here, wrap it up. Thank you very much for your time. Thank you very much for your questions.
As I said earlier on, for some of you that have been with us from the beginning, thank you very much for your support. We are in the best place we've ever been. We feel great about the future, and we expect that the fundamentals, the potential of the company will be reflected in its market price. For now, we're head down, execute, wrap up the year, and we're very excited about next year as well. Thanks again for joining.